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Abstract  31 
Objectives: The aims of the current review are (1) to give an overview of human studies 32 
investigating pharmacotherapy to ameliorate visuospatial neglect, and (2) to evaluate the 33 
quality of those studies.  34 
Methods: A systematic literature search using PubMed, Scopus, and ResearchGate was 35 
conducted in regard to studies that evaluated pharmacological interventions aiming to 36 
ameliorate post-stroke visuospatial neglect. The search was limited in the following features: 37 
species (human), adults (≥18 years of age), language (English), and type of neglect 38 
(visuospatial). Two independent authors extracted data on study content and effectiveness and 39 
evaluated the quality of studies and methods.  40 
Results: A total of 11 studies were identified. Three studies were considered to be of moderate 41 
quality, the others of low quality. Seven studies represent dopaminergic, three cholinergic, and 42 
one noradrenergic treatment. Three dopaminergic studies showed primarily positive effects of 43 
dopaminergic stimulation on visuospatial neglect, whereas three others showed adverse effects. 44 
All three cholinergic studies found positive effects in some outcome measures concerning 45 
visuospatial neglect. The noradrenergic stimulation improved maintaining attention when 46 
exploring space.  47 
  
 
3 
 
Conclusions: Currently, cholinergic therapy might be the best option for future research. 48 
However, we must emphasize the explorative nature and limited quality of the reviewed 49 
studies.  50 
 51 
Introduction 52 
Visuospatial neglect (VSN) is a common disorder post-stroke (1). Patients with VSN fail to 53 
report, orient toward, or respond to visual stimuli in the contralesional hemispace (1). VSN can 54 
result from left or right hemispheric lesions, but is most profound and persistent following right 55 
hemispheric lesions (2). Nearly half of all stroke patients are affected by VSN in the (sub)acute 56 
phase post-stroke (3). Estimations are that 40% (3) to 75% (3,4) of these patients develop 57 
chronic symptoms up to one year post-stroke in at least a mild form. In addition to motor 58 
impairments (5), stroke has many adverse behavioural consequences on the cognitive level, 59 
hampering participation in a wide range of everyday activities (6,7).  60 
 61 
Due to the high prevalence of post-stroke VSN and its negative consequences, effective 62 
remediation techniques are needed. Promising remediation techniques have emerged over the 63 
last decades, including prism adaptation (8–10), virtual reality training (6,11), visuospatial and 64 
scanning training (12), galvanic vestibular stimulation (13,14), transcutaneous electrical nerve 65 
stimulation (15), motivational manipulations (16), optokinetic stimulation (17), video-game 66 
based remediation (10,18), and upcoming non-invasive brain stimulation techniques such as 67 
transcranial magnetic stimulation (19,20) and transcranial direct current stimulation (21–23). 68 
However, the effectiveness of almost all techniques has not been investigated thoroughly 69 
enough to allow firm conclusions (6,24). Pharmacological techniques represent another 70 
promising remediation approach. As pharmacotherapy affects the whole brain, it addresses the 71 
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factors causing VSN, instead of using compensational techniques to conceal deficits. 72 
Therefore, pharmacotherapy will be the topic of the current review.  73 
 74 
Pharmacotherapy in VSN: a brief history 75 
Several animal studies on the effectiveness of pharmacotherapy have been published over the 76 
last three decades (25–29), and have generally focussed on dopaminergic agonists and 77 
progesterone. VSN symptoms have been assessed by regular (25,26) and Morris water mazes 78 
(26,27), adhesive removal tests (27,28), and simple observations of turn direction to stimuli 79 
(29) in a variety of induced-stroke models (25–29). In general, results showed positive effects 80 
of progesterone (26–28) and apomorphine (29) on VSN, and of amphetamine on cognitive 81 
functioning (25). Similarly, human studies on the topic emerged about three decades ago (30). 82 
Yet, in human studies pharmacotherapy does not get as much attention as the other techniques 83 
in treating VSN.  84 
 85 
How pharmacotherapy might work 86 
Neuronal functioning depends on network structures, the balance between excitation and 87 
inhibition of neurons, and the resulting impulse transmission between connected neurons. 88 
About 50 neurotransmitters have been identified, either excitatory of inhibitory (31). If a 89 
neurological condition is caused by an imbalance in excitation and inhibition while neuronal 90 
connections are functionally preserved, manipulating these electrochemical processes may 91 
improve neuronal function. Neurological ‘hypofunction’ like VSN may improve by decreasing 92 
inhibition and/or increasing excitation. In this manner, pharmacological agents can have 93 
positive therapeutic effects.  94 
 95 
  
 
5 
 
As the core symptoms of VSN comprise attention deficits, it is evident to focus on those 96 
neurotransmitters that exert their effects on attention networks. Three networks of attention can 97 
be distinguished, namely the alerting, orienting, and executive network. VSN has been 98 
associated with all of them (32–34). The alerting network is modulated by noradrenaline 99 
(33,35,36). The inhibitory or excitatory effects are complex, but in general terms noradrenaline 100 
activates the brain and body for action, which is reflected in functions like increased alertness, 101 
focus and attention. The orienting network has been linked to acetylcholine (32,33). 102 
Acetylcholine is the major neurotransmitter in the peripheral nervous system at the 103 
neuromuscular junction, but also in the autonomic nervous system. In the brain it has a 104 
modulating effect on information processing, including plasticity, arousal and sustained 105 
attention. It usually has an excitatory effect. Acetylcholine agonists can directly act on 106 
receptors and increase receptor activation. The executive network of attention is modulated by 107 
dopamine (33,35), and believed to affect the spatial bias in VSN (37). Dopamine is a 108 
neurotransmitter found in distinct dopamine pathways, with a modulating role in specific 109 
functional networks (i.e. involving reward-motivated behavior). The inhibitory and excitatory 110 
effects have effect on ion channels via a second messenger system and depend on the 111 
postsynaptic type of dopamine receptor. So, patients with VSN could benefit from 112 
pharmacological intervention through modulation of surviving neuronal networks by targeting 113 
specific neurotransmitters (38).  114 
 115 
Despite the appealing advocacy of pharmacotherapy as a means to ameliorate VSN symptoms, 116 
it appears to be largely overlooked when it comes to human treatment phase I, II, or intervention 117 
studies (i.e. evaluation of (side) effects and comparison with placebo or standard treatment). 118 
 119 
Objectives and distinctiveness 120 
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The aims of the current review are (1) to give an overview of human studies investigating 121 
pharmacotherapy to ameliorate VSN symptoms, and (2) to evaluate the quality of those studies. 122 
These aims parallel those made in a Cochrane review (39) on the pharmacological treatment of 123 
VSN, published shortly before we completed the current review. However, several differences 124 
positively distinguish the current review from the Cochrane review. First, strict inclusion 125 
criteria for a Cochrane review limited the number of reviewed studies: only (quasi-)RCTs were 126 
included, resulting in a total of two studies. 'Lower-quality' studies however should also be 127 
reported, as they may add important knowledge for future studies, especially given potential 128 
shortcomings in their designs. Additionally, we applied more criteria for assessment compared 129 
to the Cochrane review, such as the allocation of patients and blinding treatment officers, which 130 
gives a more extensive overview of the current state of art of the field. In sum, the current 131 
review provides a more comprehensive overview of available studies on pharmacological 132 
treatment of VSN and may therefore give a broader overview of the current state of art of the 133 
field. 134 
 135 
Methods 136 
Search methods and article selection  137 
Initially, the systematic literature search was performed using Pubmed, Scopus, and 138 
ResearchGate for studies published between January 2000 and July 2016 using the terms:  139 
Neglect, Visual Neglect, Spatial Hemineglect, Hemispatial Neglect, Unilateral neglect, 140 
Unilateral Spatial Neglect, Unilateral Hemispatial Neglect, Visuospatial Neglect, Visuospatial 141 
Hemi-Neglect, Spatial Neglect, Visual Inattention, Spatial Inattention, Visual Hemispatial 142 
Inattention, Hemispatial Inattention, Visual Hemineglect, Visual Hemi-Neglect, Sensory 143 
Neglect, Personal Neglect, Behavioral Neglect, Behavioural Neglect, Motor Neglect, Hemi-144 
inattention, Peri-Personal Neglect, Peripersonal Neglect, Pharmacotherapy, Remediation, 145 
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Rehabilitation, Medication, Therapy, (Nor)Epinephrine, (Nor)Adrenaline, Dopamine, and 146 
Choline. Note that ‘unilateral neglect’, ‘hemispatial neglect’, or any other inconsistent labels 147 
are under the same overall VSN syndrome, which is why those terms were included in the 148 
current search. The search was limited in the following features: species (human), adults (≥18 149 
years of age), language (English), and type of neglect (visuospatial). Intervention studies 150 
aiming at enhancing attention and/or decreasing VSN symptoms post-stroke were selected 151 
when they met the following inclusion criteria: (1) study population described patients 152 
experiencing visuospatial attention deficits resulting from stroke, and (2) the study reported 153 
outcome measures aimed directly at the VSN syndrome, or aimed at general attention, which 154 
included subtests aimed at the VSN syndrome. Due to limited search results (seven studies), 155 
we additionally released our time span criterion to include studies published in any year, and 156 
found four additional studies published prior to 2000. These studies were subsequently 157 
included for review.  158 
 159 
Two authors (J.v.d.K. and M.D.) independently conducted the search and screened the articles. 160 
Duplicates were excluded. Full-text articles were collected or requested. In case of doubt 161 
concerning inclusion, the other authors were consulted. 162 
 163 
Data extraction  164 
J.v.d.K. and M.D independently performed the data extraction. Extracted data was compared 165 
and discrepancies were discussed amongst J.v.d.K and M.D. The following study 166 
characteristics were extracted from the articles: study design, number of patients, outcome 167 
measures, p-value, effect size (calculated when possible given the reported data in the original 168 
papers), and timing of measurements. The following intervention characteristics were 169 
extracted: aim of the intervention, type of intervention, duration (minutes to weeks), and 170 
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intensity (micro- to milligrams). The following patient characteristics were extracted: 171 
diagnostic criteria, age, sex, time post-stroke, stroke type, and lesion site. 172 
 173 
Quality assessment  174 
J.v.d.K. and M.D. independently evaluated the characteristics and the quality of the selected 175 
studies. A third author (A.F.T.B.) was consulted in case of dual doubt on scoring. The 176 
methodological quality was based on the following criteria: (1) randomization of intervention 177 
or different conditions, (2) blinded allocation of the intervention, (3) blinding of patients, (4) 178 
blinding of treatment officer, (5) blinding of researchers, (6) comparability of groups at the 179 
start of the study, (7) reporting of effect size, (8) reporting completeness of follow-up, (9) equal 180 
treatment of groups, aside from intervention (40). We added three relevant elements to evaluate 181 
methodological quality: (10) comparison of an experimental and control group that received 182 
either an alternative form of treatment or no intervention, (11) group size (10 per group), and 183 
(12) time post-stroke. This 12-point checklist yielded a total score between 0 and 12 for each 184 
study, creating a natural 4-point demarcation for three groups. Studies were subsequently 185 
divided into high (total score 9), moderate (5-8), and low (4) quality studies.  186 
 187 
 188 
Results 189 
Initially, 38 articles were identified, 11 of which met the inclusion criteria (see Figure 1 for a 190 
flowchart of the article selection process). Of these studies, seven studies investigated 191 
dopaminergic therapy, three studies considered cholinergic therapy, and one study targeted 192 
(nor)adrenergic therapy. Findings of the methodological quality of the studies, based on the 193 
elements mentioned above, are presented in Table 1. There was an initial 95% agreement 194 
between J.v.d.K and M.D. regarding quality assessment, which was 100% after consultation. 195 
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None of the studies were qualified to be of high quality according to our criteria, three studies 196 
were considered to be of moderate quality (41–43) and the other eight were considered low 197 
quality studies (4,30,44–49). An overview of study and participant characteristics is listed in 198 
Table 2. Only one study (42) included a true patient control group, while the remaining ten 199 
studies (4,30,41,43–49) used an A-B(-A) design in which all individual patients served as their 200 
own control. We considered four studies in the chronic phase (4,42,45,49), one study in the 201 
sub-acute phase (47), and one study in the acute phase post-stroke (48). Time post-stoke was 202 
variable in the remaining five studies, in which both patients in the sub-acute phase and patients 203 
in the chronic phase were included (30,41,4344,46). Only five studies (43,45–47,49) focussed 204 
primarily on VSN by using exclusively VSN tests (e.g. bisection, cancellation, visual search 205 
and detection tests) as outcome measures, while six studies (4,30,41,42,44,48) focussed more 206 
generally on recovery or enhancing attention, and additionally included VSN tests in their 207 
outcome measures. None of the 11 studies reported effect sizes. Six studies reported enough 208 
data to calculate effect sizes ourselves (41–43,45–47), these are presented in Tables 3-5.  209 
 210 
Discrepancies were also observed regarding patients characteristics, such as diagnostic criteria, 211 
stroke type, and lesion site. Diagnostic criteria regarding VSN were highly variable amongst 212 
all studies and many different assessments were used in each study. Eight (4,41–44,46,47,49) 213 
out of 11 studies reported assessing VSN prior to the study. Five of these studies 214 
(42,43,46,47,49) reported patients’ scores on these assessments. Stroke type was unaccounted 215 
for in three (4,44,45) out of 11 studies. Overall, ischemic stroke was reported more frequently 216 
compared to haemorrhagic stroke. Concerning lesion site, all dopaminergic studies reported on 217 
hemispheric lesion location, which were all right-sided (4,30,41,44,46–48). The cholinergic 218 
studies all included right hemispheric patients too, with one patient in two studies showing 219 
additional left-hemispheric lesions (42,43). Additional information on affected arteries was 220 
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provided in two studies (42,43). Three studies analysed patients’ lesion sites more thoroughly 221 
by means of CT and/or MRI data (41,43,49), and the effect of specific lesion location on 222 
therapy effectiveness was evaluated in two additional studies (44,47). Moreover, discrepancies 223 
were observed concerning the nature, duration, frequency, and dosage of the medicaments 224 
used.  225 
 226 
Overall, we must emphasize the explorative nature of the reviewed studies. Comprehensive 227 
characteristics of the studies are presented per class of medicaments in Tables 3-5.  228 
 229 
Dopaminergic therapy  230 
Seven studies investigated dopaminergic therapy (4,30,41,44,46–48). One study was 231 
considered to be of moderate quality (41). The remaining six studies were considered to be of 232 
low quality (4,30,44,46–48) . 233 
 234 
First, Gorgoraptis et al. (2012) used a double-blind, placebo-controlled A-B-A design to study 235 
the effects of rotigotine on VSN, spatial working memory, selective and sustained attention 236 
and motor control. Outcome measures included an extensive battery of pen-and-paper and 237 
computerized tests (see Table 3 for a more detailed description). 16 patients received a 9.0 mg 238 
rotigotine patch on a daily basis in the B-phase for 7 to 11 days. When compared to baseline 239 
and placebo conditions, VSN performance improved on the Mesulam shape cancellation test. 240 
All other tests (assessing VSN, spatial working memory, selective and sustained attention, and 241 
motor control) failed to show improvements of function (41).  242 
 243 
Second, Fleet et al. (1987) conducted a small-sample, open-label study. Two patients were 244 
given 15 mg of bromocriptine orally for 3 to 4 weeks on a daily basis and were tested prior to, 245 
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during, and after treatment. Outcome measures included basic reaction tests (e.g. shoulder 246 
tapping and arm raising on command) and pen-and-paper neglect tests (letter, line and shape 247 
cancellation, and line bisection). One patient showed a positive result on all measures compared 248 
to both baseline performance and performance after discontinuing treatment, the other patient 249 
(this patient had a frozen shoulder and could not reliably perform two of the eight tests) showed 250 
positive results on six tests compared to baseline performance, but only on four tests compared 251 
to performance after treatment discontinuation (30). 252 
 253 
Third, Grujic et al. (1998) investigated the effect of bromocriptine on VSN. Seven patients 254 
received a single 2.5 mg dose of bromocriptine. The main outcome measure was a 255 
computerized target search paradigm. Patients were tested prior to, and after receiving their 256 
dose. Results indicated an increase of the rightward bias: bromocriptine caused six out of seven 257 
subjects to spend more time exploring the ipsilesional space and therefore the relative VSN of 258 
the contralesional left hemispace increased. Target detection accuracy and reaction time did 259 
not change in either hemispace after administration of bromocriptine compared to baseline 260 
(44).  261 
 262 
Fourth, a single case report by Barrett et al. (1999) presented an absolute adverse effect of 263 
dopaminergic stimulation. The patient received an oral dose of bromocriptine during 4 weeks, 264 
which was gradually increased until a peak dose of 20 mg was reached after 2 weeks. Forth, 265 
the dose was gradually decreased. Performance on a line bisection task worsened while taking 266 
bromocriptine, and improved when bromocriptine was terminated (47). 267 
 268 
Fifth, Geminiani et al. (1998) conducted a placebo-controlled, open-label trial in which four 269 
patients received a single subcutaneous dose of 2 mg of apomorphine on the first day of the 270 
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study, followed by a placebo injection 24 hours later. Outcome measures included a pen-and-271 
paper circle cancellation, counting, and pointing test, which were administered prior to and 272 
after apomorphine and placebo administration. Performance at a circle cancellation test was 273 
positively modified by apomorphine: all patients crossed more targets after taking apomorphine 274 
compared to baseline and placebo control. Post-apomorphine results of the counting and 275 
pointing tests did not differ significantly when compared to performance at baseline and after 276 
placebo control (46).  277 
 278 
Sixth, Mukand et al. (2001) used a case series design and included four patients to evaluate the 279 
efficacy of carbidopa L-dopa (Sinemet) on reducing left-sided VSN symptomatology. Patients 280 
received half a tablet of 25/100 mg of Sinemet 3 times daily for 2 days, followed by one tablet 281 
3 times daily for the rest of the week. Patients were tested with a shortened version of the 282 
Behavioural Inattention Test (BIT) and Functional Independent Measure (FIM) test prior to, 283 
and after this week. Three patients showed enhanced BIT scores, and all four patients showed 284 
enhanced FIM scores after Sinemet intake. Results were presented as being significant, but p-285 
values were not mentioned (48).  286 
 287 
Last, a double-blind, placebo-controlled, within-subject study was performed by Buxbaum et 288 
al. (2007), using an A-B-A design. The effect of a 100 mg amantadine injection, given twice a 289 
day, on VSN was studied in four patients. In total, 13 tests were administered, including pen-290 
and-paper tests (e.g. letter cancellation and line bisection; see Table 3 for a more detailed 291 
description) and computerized tests (i.e. Dual-Task test and the lateralized target and lateralized 292 
response test), as well as functional independency tests (Naturalistic Action Test) and 293 
questionnaires (e.g. Family Burden and Anosognosia). Reaction times on the Sustained 294 
Attention to Response Test (SART) improved significantly in two patients (patient 2 and 3), as 295 
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well as the percentage of correct responses (patient 2), and mean response times in the 296 
lateralized tests (patient 4). However, negative effects were seen on lateralized mean response 297 
times (patient 4), the Dual-Task test (patient 2), and on the number of correct responses on the 298 
SART (patient 2). All other measures showed no significant effect (4).  299 
 300 
To summarize, only one study was found to be of moderate quality. This study found a positive 301 
effect of dopaminergic therapy on VSN (41). Of the remaining (low-quality) studies, two 302 
studies found a positive effect (30,46), yet three studies found negative effects (4,44,47). The 303 
positive effects were exclusively found on one out of four (41), on six out of eight (30), and on 304 
one out of three tests (46), which were used to measure VSN. One study found a positive effect 305 
of dopaminergic therapy on measures of behavioural inattention and functional independence 306 
(48). 307 
 308 
Cholinergic therapy  309 
Three studies investigated cholinergic therapy (see Table 4). Two studies were considered to 310 
be of moderate quality (42,43), and one study was considered to be of low quality (49). 311 
 312 
Lucas et al. (2013) described the effects of nicotine on spatial attention in a small sample 313 
(n=10), double-blind, placebo-controlled within-subject study. Outcome measures included 314 
pen-and-paper Bells, letter, and shape cancellation tests, a line bisection test, and a compound-315 
word reading test, as well as computerized cued (Posner’s paradigm) and lateralized detection 316 
tests. A single, 10 mg dose of nicotine was administered through a transdermal patch. The 317 
average search performance of patients with VSN improved on all cancellation tests and in 318 
lateralized visual detection, as the number of target omissions reduced significantly and search 319 
time increased relative to placebo and baseline conditions. No significant improvement of the 320 
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attentional bias was found on line bisection, compound-word reading, and cued detection tests 321 
(43). 322 
 323 
Furthermore, an open-label, randomized, and slightly larger sampled (n=20) study was 324 
conducted by Paolucci et al. (2010) to evaluate efficacy of rivastigmine. All subjects received 325 
cognitive rehabilitation and half of the group received add-on-pharmacotherapy. This last 326 
group received 1.5 mg of rivastigmine twice a day for the first week. Thereafter, the dose was 327 
increased to 3 mg twice a day for seven more weeks. Outcome measures included a letter 328 
cancellation test, the Barrage test, a sentence-reading test, and the Wundt-Jastrow Area Illusion 329 
Test, as well functional data scores at discharge (Barthel Index and Rivermead Mobility Index). 330 
Patients who received rivastigmine showed significantly improved letter cancellation and 331 
Wundt-Jastrow scores at discharge compared to the control group. No significant differences 332 
were found at follow-up, as the non-rivastigmine group further improved, and achieved the 333 
same results as the rivastigmine group. In fact, the former group reached their maximum 334 
performance before the latter group (42).  335 
 336 
The study by Vossel et al. (2010) applied a small sample (n=9), double-blind, placebo-337 
controlled within-subject design to investigate whether cholinergic stimulation by nicotine 338 
facilitated attentional reorienting. The main measure of outcome was reaction time on a Posner 339 
cueing task. A Nicorette gum consisting of 2 mg of nicotine was chewed on for half an hour. 340 
Patients’ reaction times were lower for both valid and invalid trials after nicotine, without any 341 
differences in the magnitude of the left validity effect in the whole patient group. Responses 342 
were comparable in neutrally and uncued trials (49).  343 
 344 
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To summarize, all three studies found cholinergic therapy to significantly improve function on 345 
attentional reorienting (49), spatial attention (42,43), and functional measures (42), but only on 346 
three out of six (43), and two out of six outcome measures used in these studies (42). Most 347 
importantly, the observed positive effect in the Paolucci et al. (2010) study disappeared at 348 
follow-up, therefore rivastigmine was merely found to accelerate early-phase cognitive 349 
recovery in this study. 350 
 351 
(Nor)adrenergic therapy  352 
The only identified study on noradrenergic therapy by Malhotra et al. (2006) was considered 353 
to be of low quality (45). Three right-hemispheric patients with chronic VSN received a single 354 
placebo injection and a 29 µg/kg guanfacine injection one week apart in a counterbalanced and 355 
double-blind manner (see Table 5). Outcome measures included pen-and-paper tests (line 356 
bisection and Bells cancellation), computerized tests for measures of space exploration, single 357 
target visual search, and naming objects, as well as a sustained attention and a spatial working 358 
memory test. One patient performed significantly better after guanfacine compared to placebo 359 
on the space exploration test, as total search time increased. None of the patients performed 360 
significantly better on pencil-and-paper VSN tests after guanfacine compared to placebo (45). 361 
 362 
To summarize, even though two out of three patients cancelled more stars post-guanfacine 363 
administration, line bisection deviations increased in one of these subjects and overall 364 
performance on pen-and-paper VSN tests did not improve significantly after (nor)adrenergic 365 
therapy.  366 
 367 
Discussion 368 
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The aims of this review were (1) to give an overview of human studies investigating 369 
pharmacotherapy to ameliorate VSN, and (2) to evaluate the quality of those studies. We found 370 
11 studies, evaluating three pharmacological approaches: seven studies on dopaminergic 371 
therapy, three studies on cholinergic therapy, and one study on (nor)adrenergic therapy. Quality 372 
assessment showed that none of the reviewed studies were of high quality, only three recent 373 
studies were of moderate quality, and the eight remaining studies were of low quality, 374 
according to our criteria. None of the studies completed all full requirements of a randomized 375 
controlled trial. 376 
 377 
The results of the dopaminergic studies (one of moderate quality, six of low quality) were not 378 
consistent to draw firm conclusions: both promising effects (i.e. decrease of VSN) and increase 379 
of VSN were observed. Cholinergic treatment (two studies of moderate quality, one of low 380 
quality) was found to be effective in ameliorating VSN symptoms in all three studies. However, 381 
positive effects were measured on some, yet not all tests. Although the only (nor)adrenergic 382 
study showed some positive effects, the quality of this study was considered low, so no firm 383 
conclusions can be drawn. Moreover, none of the studies reported effect sizes, which hampers 384 
interpreting the study outcomes. Effect sizes are needed to evaluate clinical significance, while 385 
p-values only represent the randomness of the obtained effects (52). Overall, methodological 386 
limitations render us in drawing clear conclusions on the effectiveness of pharmacological 387 
treatment of VSN. 388 
 389 
Our statements are comparable to those made in a recently published Cochrane review on the 390 
pharmacological treatment of VSN, in which two identical cholinergic studies have been 391 
reviewed  (39). However, the Cochrane review included a smaller number of studies and 392 
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applied limited quality assessment criteria. The current review therefore provides a more 393 
complete overview of available studies on pharmacological treatment of VSN. 394 
 395 
Several cognitive processes appeared to be of importance regarding the potential mechanisms 396 
underlying pharmacological treatment of VSN. Cholinergic treatment  seemed to be the most 397 
effective in ameliorating VSN symptoms, which suggests the orienting, perhaps most 398 
mouldable, network of attention to play a role in VSN (32–34). Dopaminergic and 399 
(nor)adrenergic stimulation decreased VSN symptoms in some cases. Hence, the alerting 400 
(noradrenaline) and executive (dopamine) networks might influence VSN as well (32–34).  401 
 402 
In the current review, it is clear that none of the studies, no matter what class of medicaments, 403 
showed a clear-cut improvement of VSN post-stroke. Additionally, the methods of the 11 404 
reviewed studies differed too much to compare them properly on inclusion criteria, outcome 405 
measures, medicaments used, their administration and timing. This, combined with the overall 406 
moderate to low quality of the studies, renders us in recommending a specific pharmacological 407 
approach to treat VSN. Therefore, we feel that a good starting point for future pharmacological 408 
studies targeting cognitive functional improvement in general, or the amelioration of VSN in 409 
particular, should be comparability. Below, we will discuss how to target this comparability.  410 
 411 
First of all, varying diagnostic criteria and many different tests were used to assess VSN in the 412 
11 reviewed studies. This variability turns out problematic when trying to compare studies. As 413 
described in this review, positive effects of pharmacotherapy on VSN symptoms were observed 414 
on some but not all tests. In this light, a consensus on, and implementation of, a more or less 415 
standard battery of tests could help future researchers to overcome these problems of 416 
comparison. At the level of function, the most widely used tests are cancellation tests, line 417 
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bisection tests, copying and drawing. With respect to rehabilitation, tests at the level of 418 
activities of daily living should also be included. The Catharine Bergego Scale may be the 419 
solution, as this observation scale measures VSN in basic activities of daily living (53).  420 
 421 
Additionally, the more standard pen-and-paper tests (including the abovementioned 422 
cancellation tests, line bisection tests, copying and drawing) are generally regarded not 423 
sensitive enough to capture mild VSN, especially in the late sub-acute or chronic phase. The 424 
use of (tablet) computers and computerized tests would greatly improve the level of test 425 
specificity. For example, more accurate and precise reaction times can be recorded (54,55), 426 
search strategies during cancellation tests can be evaluated (56), and stimuli can be presented 427 
in a dynamic way (e.g. during cueing tests) (57). As a result, these tests are able to identify 428 
more subtle deficits that standard pen-and-paper tests might miss (54,58–60), which enables to  429 
detect VSN at the immediate moment of occurrence. Furthermore, common clinical tests might 430 
lose accuracy in the chronic phase of VSN (54). Computerized tests, on the other hand, are 431 
found to maintain accuracy, even in the chronic phase of VSN (54). Furthermore, tests in a 432 
virtual reality environment may be an effective tool to assess VSN. Virtual reality allows 433 
patients to interact with an environment similar to real-life experience, but in a safe and 434 
controlled manner (58,61). Hence, a more dynamic test is created, which provides better insight 435 
into the impairments of daily life. 436 
 437 
One more issue of future interest could lie in the promising field of neuroimaging. New 438 
techniques could help to map neural networks, thereby visualising changes induced by the 439 
medicament. Although costly, these techniques could help tackle the problems of inter-assessor 440 
variability in the assessment of clinical observations and problems related to the standardized 441 
testing of cognitive skills.  442 
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 443 
With respect to the pharmacological treatments, many different substances and subsequent 444 
doses were used in the reviewed studies. However, none of the reviewed studies analysed the 445 
variability in dose-responses. In our opinion, future research should aim to make inferences on 446 
the effects of medicaments based on a spectrum of doses within the analysis of a medicament. 447 
In this way, information could be gathered on the strength and duration of the pharmaceutical 448 
effect. This should allow future researchers to make clearer recommendations in the 449 
remediation of VSN. 450 
 451 
Importantly, time post-stroke was highly variable in the reviewed studies. Studies were 452 
conducted with patients in both sub-acute and chronic phase post-stroke. However, only results 453 
of studies with patients in the chronic phase post-stroke can be reliably taken into account, as 454 
up to 3 months spontaneous recovery could have been achieved (3,62). In case patients in the 455 
sub-acute phase post-stroke are included, a control group is necessary for future research to 456 
monitor the effects of spontaneous recovery. Only one of our 11 reviewed studies included a 457 
control group (42), all the others lacked this important feature. 458 
 459 
The addition of a follow-up phase would also positively add to the level of information 460 
gathering. Only one of the reviewed studies included a follow-up phase in which participants 461 
were assessed one month post-treatment. Thus, in the other 10 studies, no information was 462 
given regarding the duration of the beneficial influence of pharmaceutical treatment. Future 463 
research should be able to tackle this problem and include one or more follow-up 464 
measurements, ideally up to 3 months post-treatment. However, shorter timeframes are the 465 
primary concern, as they will possibly reduce outcome variation due to events unrelated to the 466 
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study and therefore allow for the accurate assessment of functional outcomes and drug safety 467 
(63).  468 
 469 
Study limitations  470 
The aim of the current review was to give an overview of human studies investigating 471 
pharmacotherapy to ameliorate VSN, thereby leaving out a substantial amount of data/results 472 
from animal studies targeting disorders of attention and/or VSN with pharmacological 473 
treatment. Although human studies are most relevant for rehabilitation purposes, results on 474 
timing of treatment, timing of drug administration, dose-response interactions, and lesion site 475 
differences from animal studies might have given better insight into how to set up better human 476 
studies. 477 
 478 
Another limitation could lie in our selection process. We excluded studies in which attention 479 
deficits were treated, based on the lack of outcome measures aimed at the VSN syndrome. In 480 
fact, several human studies used pharmacotherapy as a treatment of attention and cognitive 481 
impairments after stroke (64–70). For example, both Jorge et al. (2010) and Adams et al. (2012) 482 
found that anti-depressives may enhance motor and cognitive recovery after stroke (68,69). 483 
Perhaps, anti-depressives could also beneficially influence recovery from VSN post-stroke. 484 
Therefore, these animal and human studies should be kept in mind regarding future 485 
investigation.  486 
 487 
 488 
Conclusions  489 
In conclusion, due to the methodologically weak quality of nearly all reviewed studies, we 490 
cannot make any clear-cut inferences on the effectiveness of pharmacotherapy on VSN post-491 
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stroke. Nevertheless, regarding the three substances, we cautiously consider cholinergic 492 
therapy to be the most promising in treating VSN. Therefore, we believe future research should 493 
focus on cholinergic therapy.  494 
 495 
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